Clinical Monitoring Featured Articles
-
Precision Medicine, Trial Design, And Patient Centricity Will Remain Hot In 2016
12/29/2015
Jennifer Reichuber, co-founder and principal at Altani Associates, has been a consultant to pharma and biotech companies for about four years. Prior to becoming a consultant, she was involved in clinical development at a Big Pharma company for 15 years. Her experience in healthcare, tech, and pharma, and as a consultant, has given her insights into the challenges these companies face, and their outlook on trends for 2016.
-
Mobile Devices And RBM Expected To Drive Trial Efficiencies In 2016
12/22/2015
Jonathan Zung has logged over 20 years in the pharma industry, and holds a resume that includes executive positions with both Bristol-Myers Squibb and Pfizer. He is currently the VP, Head of Global Clinical Sciences & Operations for UCB and serves as Chair of the TransCelerate BioPharma Operations Committee. I recently spoke with Zung about the trends that he believes have the greatest potential to impact clinical trials in 2016.
-
Lilly Expects Patient Centricity, Adaptive Trials, And New Technologies To Deliver In 2016
12/17/2015
As the VP of Portfolio Management at Eli Lilly and Company, Anne White spends a good deal of time staying close to clinical trials, patients, and the latest trends affecting them. In her 24 years in pharma, most of them at Lilly, she has served as VP of Oncology Development Operations and Senior Director of Global Strategic Planning and Patient Tailoring. In this Q&A article, White shares her thoughts on pharma becoming more patient-centric and the increasing move towards more adaptive trials.
-
Clinical Leader Expands Editorial Advisory Board
12/17/2015
Clinical Leader relies on the feedback of pharma industry professionals and consultants to guide its focus and direction. The website’s editorial advisory board, composed of consultants and executives from the pharma and bio industries, help guide the direction and focus of the site’s editorial content. Clinical Leader has announced that in 2015 it added 17 distinguished individuals to that board, including representatives of Eli Lilly and Company, Pfizer, The Avoca Group, PatientsLikeMe, BMS, Novartis, Shire, and more.
-
2016 Trends: Patient Advocacy, Partnering, And New Technologies Lead The Way
12/16/2015
James Gillespie, CEO of the Center for Healthcare Innovation, believes we are entering a golden era of healthcare, including clinical trials. “There is so much change afoot that this will truly be an exciting time in the U.S. healthcare system,” he says. “But with that change we’ll also see a number of challenges the industry will need to overcome.” In this Q&A article, Gillespie discusses how patient advocacy efforts, new technologies, and partnering models will help shape the future of clinical trials.
-
Managing the Long-Term Medical Expenses of Adverse Drug Events
12/10/2015
Pharmaceutical developers purposefully enroll subjects who are relatively homogenous in pre-approval clinical trials. They do this to help obtain clear statistical descriptions regarding a compound’s efficacy. Safety profiles, however, can differ greatly between such homogenous pre-approval patients and the heterogeneous population of real world patients.
-
Quintiles Chairman Reflects On 33 Years In Drug Development
12/8/2015
On December 31, 2015 Dennis Gillings will officially step down as the Executive Chairman of Quintiles. When Gillings began working with pharma companies in 1974, shortly after coming to the U.S. from England, he was a professor of biostatistics at the University of North Carolina at Chapel Hill. His career in pharma started when he received a call from Hoechst, which later became Aventis and, subsequently, Sanofi
-
WIB Profile: Will Partnering Models Continue To Evolve In 2016?
12/7/2015
I recently spoke to Reichuber about clinical trends we might expect to see in 2016. She feels the industry continues to undergo change in regard to partnering agreements. But are strategic partnerships going away or just evolving? And in what areas do small pharma and biotech firms really need the most help? In this Q&A article, the co-founder and principal of Altani Associates shares her thoughts.
-
Are Patient Surveys The Missing Link To Successful Recruitment & Retention?
12/3/2015
While patient recruitment and retention have been an issue in the delay and expense of clinical trials for decades, patient centricity has at least temporarily moved to the forefront in the clinical space. Although often discussed as two separate issues, there is no question the two are intertwined. Integrating the patient voice in the protocol design process will certainly lead to better recruitment outcomes and patients who are more willing and able to adhere with a study for its duration.
-
IN CASE YOU MISSED IT: Clinical Leader Top 3 Articles For November 2015
12/2/2015
Below are my top three articles downloaded on Clinical Leader for the month of November 2015. In case you missed them, please take this opportunity to see what everyone else was learning about electronic health records, patient centricity, and planning for clinical success.